Equity Overview
Price & Market Data
Price: $0.171
Daily Change: +$0.0066 / 3.86%
Daily Range: $0.156 - $0.175
Market Cap: $12,654,542
Daily Volume: 1,419,651
Performance Metrics
1 Week: 3.46%
1 Month: -43.20%
3 Months: -86.03%
6 Months: -54.60%
1 Year: -62.02%
YTD: -69.98%
Company Details
Employees: 76
Sector: Health technology
Industry: Biotechnology
Country:
Details
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.